EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and safety of generic tofacitinib in spondyloarthritis: A real‐world retrospective analysis from India

Sanat Phatak iD, Aditya Khenat, Mansi Malandkar, Sanjiv Amin

International Journal of Rheumatic Diseases · 2023-03 · 26 (3) · 487-492

DOI: 10.1111/1756-185x.14570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 20.01.2023. Verfasst von Sanat Phatak und 3 weiteren Autor:innen. Beteiligte Einrichtung: K.E.M. Hospital Research Centre, Pune, India. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Psoriatic, COVID-19, Spondylarthritis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trial evidence demonstrates the efficacy of tofacitinib in ankylosing spondylitis and psoriatic arthritis (PsA). Real‐world data from spondyloarthritis (SpA) patients are scarce; there are few reports of its effectiveness and safety from low‐ to middle‐income countries like India, despite its widespread usage.

Methods

This was a retrospective analysis of clinical and laboratory records of 100 patients with SpA prescribed generic tofacitinib from a single center in Mumbai, India. Disease activity was measured using the Ankylosing Spondylitis Disease Activity Score C‐Reactive Protein (ASDAS‐CRP) in all patients, along with disease‐specific outcome measures in the subgroups. We used paired t test for response to tofacitinib. We compared Δ ASDAS‐CRP in patients with active peripheral arthritis and in patients without. We defined clinical tofacitinib failure as the physician's decision to change or add a disease‐modifying antirheumatic drug (DMARD), and performed logistic regression to identify factors associated with tofacitinib failure.

Results

Among 100 patients (71 male, median age 42.5 years), 57 had axial SpA, 10 had peripheral SpA, 4 had inflammatory bowel disease‐SpA and 29 had PsA. One‐third had received biologic DMARDs previously. Patients received tofacitinib for a median of 192 days. There was a significant improvement in ASDAS‐CRP in all types of SpA. Patients with active peripheral arthritis had a significantly greater fall in ASDAS‐CRP. There were no serious adverse events, 19 patients had mild COVID‐19; no patient had tuberculosis. Ten patients had tofacitinib failure; no baseline parameter could predict failure.

Interpretation

In the real‐world setting, generic tofacitinib showed good effectiveness and tolerable safety profile in Indian patients with SpA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, PsoriaticCOVID-19SpondylarthritisSpondylitis, AnkylosingAdultHumansMaleRetrospective StudiesFemalePiperidinesPyrimidines

Stichwörter der Autor:innen

South Asiagenericregistryspondyloarthritistofacitinib

Substanzen

Antirheumatic AgentstofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • K.E.M. Hospital Research Centre, Pune, India.
  • B.J. Medical College and Sassoon General Hospital, Pune, India.
  • Rheumatic Disease Clinic, Mumbai, India.

ORCID-Profile: Sanat Phatak

Zitieren

APA

Phatak, S., Khenat, A., Malandkar, M., & Amin, S. (2023). Effectiveness and safety of generic tofacitinib in spondyloarthritis: A real‐world retrospective analysis from India. International Journal of Rheumatic Diseases, 26(3), 487-492. https://doi.org/10.1111/1756-185x.14570

Vancouver

Phatak S, Khenat A, Malandkar M, Amin S. Effectiveness and safety of generic tofacitinib in spondyloarthritis: A real‐world retrospective analysis from India. International Journal of Rheumatic Diseases. 2023;26(3):487-492. doi:10.1111/1756-185x.14570

BibTeX
@article{Phatak2023,
  author = {Phatak, Sanat and Khenat, Aditya and Malandkar, Mansi and Amin, Sanjiv},
  title = {Effectiveness and safety of generic tofacitinib in spondyloarthritis: A real‐world retrospective analysis from India},
  journal = {International Journal of Rheumatic Diseases},
  year = {2023},
  volume = {26},
  number = {3},
  pages = {487--492},
  doi = {10.1111/1756-185x.14570}
}
Kostenlos starten →